Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived from Spontaneous Reports of Adverse Drug Reactions

Abstract

Introduction:

Considering the antidepressant agomelatine (AGM) there is a discrepancy between the widespread knowledge of the potential of AGM to cause hepatotoxic adverse drug reactions (ADR) and the availability of corresponding published data. This impedes an adequate assessment of the hepatotoxicity profile of AGM.

Methods:

We conducted a query of the database of a German Medical Regulatory Body (BfArM) and analyzed spontaneous reports of hepatotoxic ADR.

Results:

We identified n=58 cases of AGM-related hepatotoxic ADR. Most frequent ADR was asymptomatic increase of liver enzymes (79%); n=6 patients (10%) with AGM-related toxic hepatitis were reported. Characteristics of patients: female sex (69%), age > 50 years (mean 54 years), polypharmacy (57%), and presence of cardiovascular risk factors (58.5%). Most of the hepatotoxic ADR (90%) were reported to have improved/recovered after discontinuation of AGM.

Discussion:

Our evaluation suggests that AGM features a potential to cause severe forms of hepatotoxicity and emphasizes that a pre-existing liver disease is a contraindication for treatment with AGM. Secondly, increased age, female sex and polypharmacy may be risk factors for the development of AGM-related hepatotoxic ADR.

Key words

adverse drug reactions - antidepressants - hepatopathy - liver enzymes - melatonin - pharmacovigilance

• References

• 1 EMA Agomelatine. Summary of product characteristics. EMA 2009
• 2 Kennedy S, Eisfeld B. Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatric Dis Treat 2007; 3: 423-428
• 3 Lerner A, Case J, Takahashi Y et al. Isolation of melatonin, the pineal factor that lightens melanocytes. J Am Chem Soc 1958; 80: 2587
• 4 Nordlund J, Lerner A. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metabol 1977; 45: 768-774
• 5 Brzezinski A, Vangel M, Wurtman R et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50
• 6 Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009; 23 ((Suppl.2)) 27-34
• 7 Fornaro M, Prestia D, Colicchio S et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropsychopharmacol 2010; 8: 287-304
• 8 Masson-Pévet M, Recio J, Guerrero H et al. Effects of two melatonin analogues, s-20098 and s-20928, on melatonin receptors in the pars tuberalis of the rat. J Pin Res 1998; 25: 172-176
• 9 San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008; 23: 396-402
• 10 Wehr T. Photoperiodism in humans and other primates: Evidence and implications. J Biol Rhythms 2001; 16: 348-364
• 11 Duxon M, Flanagan T, Reavley A et al. Evidence for expression of the 5-hydroxytryptamine_2B receptor profile in the rat central nervous system. Neuroscience 1997; 76: 323-329
• 12 Millan M, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antangonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964
• 13 Millan M, Marin P, Kamal M et al. The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors. Int J Neuropsychopharmacol 2010; 14: 768-783
• 14 Rosen R, Lane R, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67-85
• 15 Landolt H, Meier V, Burgess H et al. Serotonin-2-receptors and human sleep: effects of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999; 21: 455-466
• 16 Landolt H, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: Mutual improvement of sleep, cognition, and mood?. Eur J Neurosci. 2009. 29. 1795-1809
• 17 Stahl S. Novel mechanisms of antidepressant action: norepinehprine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol 2007; 10: 575-578
• 18 EMA . CMHP assessment report for valdoxan. London: 2008
• 19 Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009; 10: 117-126
• 20 Singh S, Singh V, Nilamadhab K. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2012; 15: 417-428
• 21 Froböse T, Slawik H, Schreiner R et al. Agomelatine improves sleep in a patient with fatal familial insomnia. Pharmacopsychiatry 2012; 45: 34-36
• 22 Zajecka J, Schatzberg A, Stahl S et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010; 30: 135-144
• 23 Loo H, Hale A, D’Haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-247
• 24 Kennedy S, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 223-244
• 25 Olié J, Kasper S. Efficacy of agomelatine, a MT₁/MT₂ receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Psychopharmacol 2007; 10: 661-673
• 26 Stahl S, Fava M, Trivedi M et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010; 71: 616-626
• 27 Hale A, Corral R-M, Menacci C et al. Superior antidepressant efficacy results of agomelatine vs. fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010; 25: 305-314
• 28 Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-1732
• 29 Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109-120
• 30 Kennedy S, Rivzi S, Fulton K et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329-333
• 31 DeBerardis D, Di Iorio G, Acciavatti T et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurolog Dis Drug Targ 2011; 10: 119-132
• 32 Montgomery S, Kennedy S, Burrows G et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280
• 33 Loo H, Daléry J, Macher J et al. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. L’Encephale 2003; 29: 165-171
• 34 Imboden C, Hatzinger M. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report. Pharmacopsychiatry 2012; 45: 162-163
• 35 Vuppalanchi R, Hayashi P, Chalasani N et al. Drug-Induced Liver Injury Network (DILIN). Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010; 32: 1174-1183
• 36 Nelson S, Mitchell J, Snodgrass W et al. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J Pharmacol Exp Ther 1978; 206: 574-585
• 37 Tabak F, Gunduz F, Tahan V et al. Sertraline hepatotoxicity: report of a case and review of the literature. Dig Dis Sci 2009; 54: 1589-1591
• 38 Collados V, Hallal H, Andrade R. Sertraline hepatotoxicity: report of a case and review of the literature. Dig Dis Sci 2010; 55: 1806-1807
• 39 Yildirim B, Tuncer C, Ergun M et al. Venlafaxine-induced hepatotoxicity in a patient with ulcerative colitis. Ann Hepatol 2009; 8: 271-272
• 40 Larrey D, Rueff B, Pessayre D et al. Cross hepatotoxicity between tricyclic antidepressants. Gut 1986; 27: 726-727
• 41 Stuhec M. Agomelatine-induced hepatotoxicity. Wien Klin Wochenschr 2013; 125: 225-226
• 42 Laux G, Group VS. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry 2012; 45: 284-291
• 43 Howland R. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disorder. Neuropsychiatric Dis Treat 2009; 5: 563-576
• 44 Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923
• 45 Canbay A, Chen S, Gieseler R et al. Overweight patients are more susceptible for acute liver failure. Hepatogastroenterology 2005; 52: 1516-1520
• 46 Schwabe U, Paffrath D. Arzneiverordnungsreport 2011. In: Berlin, Heidelberg: Springer; 2011
• 47 Howland R. Publication bias and outcome reporting bias: agomelatine as a case example. J Psychosoc Nurs Ment Health Serv 2011; 49: 11-14
• 48 Howland R. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011; 34: 709-731
• 49 Jacob D, Marrón B, Ehrlich J et al. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure. Drug Healthc Patient Saf 2013; 5: 105-112